BRYXTA 400 INJECTION 16 ML

BRYXTA 400 INJECTION 16 ML is a recombinant monoclonal antibody that belongs to the immunotherapy class of cancer treatment. It can either be used as monotherapy or in combination with chemotherapy or immunotherapy medications to improve the overall survival rate.

While for women with reproductive potential subjected to BRYXTA 400 INJECTION 16 ML, it is advised to discuss with your doctor regarding effective birth control methods during the treatment. Also, continue for a minimum of 6 months after treatment course completion as this medicine may impair fertility.

BRYXTA 400 INJECTION 16 ML is associated with increased risk of bleeding complications and poor wound healing. Hence, it is suggested to avoid planning for surgery and maintain an interval of 28 days before or after surgery.

All the side effects that are relatively caused by BRYXTA 400 INJECTION 16 ML occur until the drug concentration stays in the body. It is found that this medicine will be contained in our body for almost 4 months after the final dose.

BRYXTA 400 INJECTION 16 ML is given intravenously through infusion, and the amount of drug will be measured based on the patient’s body weight, height, and age. The first dose will be administered for 90 minutes, and if well tolerated, the infusion time can be reduced to 30 minutes.

Inform your physician before starting your treatment with BRYXTA 400 INJECTION 16 ML in case you are pregnant or planning for pregnancy, as this medicine may cause harm to the unborn baby and interrupt the formation of blood vessels.

Yes, BRYXTA 400 INJECTION 16 ML can interact with other drugs. Always inform your doctor about all medications you are taking.

Before taking BRYXTA 400 INJECTION 16 ML, it is important to inform your physician if you have conditions involving inflammation in the stomach (ulcer, colitis), experience allergic reactions to BRYXTA 400 INJECTION 16 ML or its ingredients, have recently undergone surgery (associated with risk of bleeding), or have diabetes, hypertension, or heart problems.

BRYXTA 400 INJECTION 16 ML contains BEVACIZUMAB as the active ingredient.

BRYXTA 400 INJECTION 16 ML is used to treat various types of cancer.

BRYXTA 400 INJECTION 16 ML is an anti-cancer medicine that works by targeting factors that help tumors grow.